Skip to content
value.today
TherapeuticsMD, Inc. logo

TherapeuticsMD, Inc.

TXMD
$23 Mmarket cap on Oct 14, 2026-5.5% since Jan 2024
Compare
World rank
#23,947
Revenue
$3 M
For year ending December-2025
Net income
$-1 M
-18.9% margin
SEC filing
Employees
—

TherapeuticsMD, Inc. in brief

TherapeuticsMD, Inc. is a listed company in the Pharmaceutical industry, based in Boca Raton, Florida, USA. Its market value was $23 M on 14 October 2026, which makes it the 23,947th largest listed company in the world and the 4,123rd largest in the USA on this site. In the year to December 2025 it had sales of $3 M and a net loss of $1 M. Marlan D. Walker is its chief executive. By market, the largest shares of its 2025 sales came from USA (59%). Its shares trade under the symbol TXMD (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About TherapeuticsMD, Inc.

TherapeuticsMD is a Innovative Pharmaceutical company exclusively committed to advancing the health of women and championing awareness of their healthcare issues. It develops product to address the unique changes and challenges women experience throughout the various stages of their lives with a therapeutic focus in family planning, reproductive health and menopause management. The company annual revenue is 19.3 million USD and 241 employees as on 2020. The headquarters is in USA.

TherapeuticsMD, Inc. timeline

5 events, 1995–2022
  1. 1995
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 1997
  4. ✎
    Renamed Croff Enterprises Inc
    Formerly Croff Oil Co.
  5. 2009
  6. ✎
    Renamed AMHN, Inc.
    Formerly Croff Enterprises Inc.
  7. 2011
  8. ✎
    Renamed TherapeuticsMD, Inc.
    Formerly AMHN, Inc..
  9. 2022
  10. 💰
    Record revenue of $70 million
    FY2022, the highest of the 7 years on record.

Events of TherapeuticsMD, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$174 M$349 M$523 M$698 M2020202120222023202420252026

World rank over time

▼ down 14,350 places since 2020
2020-01-01: #9658#9,65820202021-01-01: #12785#12,78520212022-01-07: #20129#20,12920222022-12-25: #24834#24,83420222023-07-30: #26072#26,07220232024-01-05: #28096#28,09620242026-03-08: #11789#11,78920262026-08-01: #21386#21,38620262026-10-14: #24008#24,0082026

Rank in USA: #2,271 (Jan 2020) · #2,796 (Jan 2021) · #4,018 (Jan 2022) · #4,739 (Dec 2022) · #4,840 (Jul 2023) · #4,310 (Jan 2024) · #2,277 (Mar 2026) · #3,912 (Aug 2026) · #4,090 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
174.5×
Price / sales (TTM)
6.1×
Price / book
0.8×
Free cash flow yield
-629.0%
Net margin (TTM)
3.5%
Operating margin
-145.4%
Return on equity
0.5%
Liabilities / assets
28.6%
Net debt
$123M
Revenue growth
+71.6%
R&D / revenue
16.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $16M, net income $-133M$16MFY18Fiscal year ending Dec 2019: revenue $50M, net income $-176M$50MFY19Fiscal year ending Dec 2020: revenue $65M, net income $-184M$65MFY20Fiscal year ending Dec 2021: revenue —, net income $-172M—FY21Fiscal year ending Dec 2022: revenue $70M, net income $112M$70MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-10M$1MFY23Fiscal year ending Dec 2024: revenue $2M, net income $-2M$2MFY24Fiscal year ending Dec 2025: revenue $3M, net income $-1M$3MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$3M+71.6%$-4M$-1M-18.9%
Dec 2024$2M+35.4%$-6M$-2M-123.9%
Dec 2023$1M-98.1%$-9M$-10M-790.8%
Dec 2022$70M—$1M$112M160.1%
Dec 2021——$-80M$-172M—
Dec 2020$65M+30.7%$-156M$-184M-282.9%
Dec 2019$50M+208.4%$-151M$-176M-354.8%
Dec 2018$16M—$-130M$-133M-823.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$2M——$-0.05—
Dec 2024$1M——$-0.19—
Dec 2023$-23M——$-0.99—
Dec 2022$9M——$11.96—
Dec 2021$-143M$0M$-143M$-21.66—
Dec 2020$-159M$0M$-160M$-0.67—
Dec 2019$-166M$2M$-168M$-0.72—
Dec 2018$-107M$0M$-107M$-0.59—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$4M
Net income, trailing 12 months
$0M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $0M$1MDec ’24Three months to Mar 2025: revenue $0M, net income $-1M$0MMar ’25Three months to Jun 2025: revenue $1M, net income $1M$1MJun ’25Three months to Sep 2025: revenue $1M, net income $0M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $1M, net income $-1M$1MDec ’25Three months to Mar 2026: revenue $1M, net income $0M$1MMar ’26Three months to Jun 2026: revenue $1M, net income $0M$1MJun ’26Three months to Sep 2026: revenue $1M, net income $0M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+61.5% on a year earlier), net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of TherapeuticsMD, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$3 M
Operating income
$-4 M
Net income
$-1 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$38 M
Total liabilities
$11 M
Total equity
$27 M

As of December-2025

Top 46 institutional investors in TherapeuticsMD, Inc.#

As of Sep 30, 2026
46 institutions held 3.7 M shares (about 32.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 29.8%. Filings read through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in TherapeuticsMD, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Rubric Capital Management LP1,192,1910 (0.00%)10.30%$2 MNov 16, 2026
2Clearline Capital LP635,2220 (0.00%)5.49%$1 MNov 16, 2026
3Vanguard Capital Management LLC394,397+40,700 (+11.51%)3.41%$1 MNov 13, 2026
4ADAR1 Capital Management, LLC342,4470 (0.00%)2.96%$1 MNov 16, 2026
5Tejara Capital Ltd327,282-17,200 (-4.99%)2.83%$1 MNov 9, 2026
6Renaissance Technologies LLC142,199-4,400 (-3.00%)1.23%$0 MNov 12, 2026
7Morgan Stanley128,977-240 (-0.19%)1.11%$0 MNov 13, 2026
8BlackRock, Inc.115,1450 (0.00%)0.99%$0 MNov 13, 2026
9Geode Capital Management, LLC106,851+1,002 (+0.95%)0.92%$0 MNov 6, 2026
10Citadel Advisors LLC64,787-21,308 (-24.75%)0.56%$0 MNov 16, 2026
11Vanguard Fiduciary Trust Co63,8310 (0.00%)0.55%$0 MNov 13, 2026
12HRT Financial LP42,103+27,376 (+185.89%)0.36%$0 MNov 13, 2026
13State Street Corp30,1000 (0.00%)0.26%$0 MNov 12, 2026
14Dimensional Fund Advisors LP23,922+4,203 (+21.31%)0.21%$0 MNov 4, 2026
15Northern Trust Corp18,5560 (0.00%)0.16%$0 MNov 16, 2026
16Bridgeway Capital Management, LLC16,705-295 (-1.74%)0.14%$0 MNov 16, 2026
17Empowered Funds, LLC16,705New0.14%$0 MNov 13, 2026
18Ashton Thomas Private Wealth, LLC16,581New0.14%$0 MNov 3, 2026
19US Bancorp \de\14,740+14,494 (+5891.87%)0.13%$0 MNov 5, 2026
20XTX Topco Ltd10,683-10,563 (-49.72%)0.09%$0 MNov 16, 2026
21Vanguard Global Advisers, LLC4,9370 (0.00%)0.04%$0 MNov 13, 2026
22UBS Group AG3,028-1,632 (-35.02%)0.03%$0 MNov 10, 2026
23Tower Research Capital LLC (TRC)1,814+232 (+14.66%)0.02%$0 MNov 16, 2026
24SBI Securities Co., Ltd.1,2630 (0.00%)0.01%$0 MOct 22, 2026
25Royal Bank Of Canada842+9 (+1.08%)0.01%$0 MNov 16, 2026

All 46 institutional investors: 26 to 46, with who bought and sold →

Mutual funds holding TherapeuticsMD, Inc.#

11 funds hold shares worth $1 M (about 4.2% of the company). Since their previous reports 2 added shares and 3 sold, buying $0 M net.
Mutual funds holding TherapeuticsMD, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.244,317$1 M2.1%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.109,380$0 M0.95%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC65,183$0 M0.56%<0.01%−3.0%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC17,000$0 M0.15%0.03%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC15,320$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC14,835$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,826$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 The Gabelli ABC FundGabelli Funds, LLC3,600$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP3,612$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP3,076$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors745$0 M<0.01%<0.01%no changeJun 30, 2026

As of Jul 31, 2026

Insider trading at TherapeuticsMD, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$14 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$14 K
open market only
Insiders on file
27
since
$14 K-$44 K$0Dec 2023: bought $0 (0 trades), sold $44 K (2 trades)Dec 23Aug 2024: bought $9 K (2 trades), sold $0 (0 trades)AugApr 2025: bought $3 K (4 trades), sold $0 (0 trades)AprDec 2025: bought $14 K (1 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
TherapeuticsMD, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Tommy G. ThompsonDirectorBuy+8,400$1.670$14 K23,179Form 4
filed Marlan D. WalkerChief Executive OfficerBuy+490$1.000$49073,639Form 4
filed Tommy G. ThompsonDirectorBuy+325$1.000$32514,779Form 4
filed Marlan D. WalkerChief Executive OfficerBuy+1,167$0.860$1 K73,149Form 4
filed Marlan D. WalkerChief Executive OfficerBuy+1,136$0.870$98871,982Form 4
filed Gail K. NaughtonDirectorOption exercise+8,500——8,500Form 4
filed Marlan D. WalkerChief Executive OfficerOption exercise+3,467——66,032Form 4
filed Cooper C. CollinsDirectorOption exercise+8,500——60,516Form 4

Markets and events: TherapeuticsMD, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
31,319
0.3% of shares · 1.47 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-50 reverse split

Trading halts

  • 2025-01-03 14:32 UTC, code LUDP, resumed 14:37 UTC

Fails to deliver

  • : 193 shares at $1.96
  • : 535 shares at $2.02
  • : 54 shares at $2.19
  • : 19 shares at $2.18
  • : 2 shares at $2.11

TherapeuticsMD, Inc. scorecard#

Passes 5 of the 15 checks that could be worked out: strongest in growth (2 of 3), weakest in profitability (0 of 5). Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation1 of 2
  • Growth2 of 3
  • Profitability0 of 5
  • Financial health1 of 4
  • Shareholder returns1 of 1

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from TherapeuticsMD, Inc.'s statements, beside the median of Pharmaceutical.

TherapeuticsMD, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-145.4%1.8%
Net margin-18.9%-1.5%
Return on equity-2.1%-0.9%
Revenue growth71.6%7.3%

5of 7on the Piotroski tests of financial strength

  • Net loss of $1 million, the 3th loss-making year in a row.
  • Operating income covers the interest bill only -439.0 times.

TherapeuticsMD, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

TherapeuticsMD, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue3.01.81.3702.6r65r50r161719
Cost of revenue———1.41.4r16r6.3r2.72.64.2
Gross profit——1.3691.2r49r43r131415
Research and development————7.110r20r273454
Selling, general and administrative—4.78.9——1931741165851
Selling and marketing————108117114———
General and administrative6.96.18.957r81r7760———
Operating expenses7.47.9r9.86781r204r195r14492105
Operating income−4.4−6.1r−8.51.2−80r−156r−151r−130−78−90
Interest and finance income0.10.1———————0.0
Interest expense and finance costs0.00.0r0.30.2r3329r17r4.7——
Other non-operating income (expense)3.73.8r0.8−0.10.3r−28r−25r−2.40.70.4
Income before tax−0.7−2.3−7.71.1−79r−184r−176r−133−77−90
Income tax—−0.0−0.0———————
Income from continuing operations−0.7−2.3−7.71.1−79—————
Income from discontinued operations0.10.1−2.6111−93—————
Net income attributable to shareholders−0.6−2.2−10112−172−184r−176r−133−77−90
Earnings per share, basic-0.05-0.19-0.99r12.41-21.66r-0.67-0.72-0.59-0.37-0.46
Earnings per share, diluted-0.05-0.19-0.99r11.96-21.66r-0.67-0.72-0.59-0.37-0.46
Shares, weighted average (basic)1212r0.0r9.08.0r276246———
Shares, weighted average (diluted)1212r0.0r9.48.0r276r246r225206196
Balance sheet
Cash and cash equivalents7.55.14.33865r80r161162127132
Receivables————3632r24114.34.5
Inventory————7.68.0r123.31.51.1
Other current assets3.43.64.06.05.9r7.5r11116.62.3
Current assets14121255119128r208187140139
Property, plant and equipment———0.10.8r1.9r2.50.50.40.5
Right-of-use (leased) assets5.36.16.97.68.29.6r10———
Other intangible assets3.84.36.16.97.1r41r5.34.13.12.4
Non-current assets———————253.22.5
Total assets38394390169182r266212143142
Accounts payable0.40.30.02.23.4r21r19234.17.4
Debt due within a year————188—————
Current liabilities4.85.26.94725359r53411315
Long-term debt————0238r19573——
Lease liabilities (non-current)5.15.56.57.48.18.7r9.1———
Non-current liabilities—————246204———
Total liabilities11111455263306r25711413—
Retained earnings−952−952−950−939−1,051−879r−695−519−387−310
Shareholders' equity27272935−94−124r9.2r98r130127
Total liabilities and equity38394390169182r266212143142
Shares outstanding1212129.58.6r300r271240216197
Cash-flow statement
Depreciation and amortization0.40.50.91.20.7r4.1r1.4r0.30.20.1
Share-based compensation0.10.31.3121811r11r8.76.917
Cash from operating activities2.51.2−239.4−143−159r−166r−107−76−69
Capital expenditure————−0.0−0.2r−2.5r−0.2−0.1−0.4
Intangible assets bought———−0.4−2.2−1.4r−1.4r−1.1−0.8−0.8
Cash from investing activities———−0.4−2.2−1.6r−24r−21−0.8−1.3
Debt issued———————75——
Debt repaid———−219−50—−82———
Shares issued——3.22.518432r77r9069135
Cash from financing activities——3.2−23513081r189r16373137
Report10-K/A10-K/A10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

What TherapeuticsMD, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

As of Dec 31, 2025

Executive pay at TherapeuticsMD, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2024
$759 K
Marlan Walker
Other top executives, average
$120 K
the CEO earned 6.3× this
$100 invested is now
$2
TherapeuticsMD, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2024Marlan Walker$759 K$759 K$120 K$2
2023Marlan Walker$1.0 M$889 K$685 K$4
2022Hugh O’Dowd, Brian Bernick, Marlan Walker, Mark Glickman$3.7 M$420 K$561 K$9

As of Dec 31, 2024

Events at TherapeuticsMD, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 1 · Material agreement 1 · Shareholder vote 2 · Results announced 14

TherapeuticsMD, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Auditor changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Results announced8-K

As of Nov 13, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of TherapeuticsMD, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$1 MPrivate placement after listingUnder $2 million2equitySEC
Oct 2022$7 MPrivate placement after listing$2 to $10 million6equity, optionsSEC
Sep 2022$7 MPrivate placement after listing$2 to $10 million6equity, optionsSEC
Jul 2022$15 MPrivate placement after listing$10 to $50 million6equity, optionsSEC
Aug 2020$8 MPrivate placement after listing$2 to $10 million3optionsSEC
Sep 2012$9 MNo. 1$2 to $10 million8equitySEC

Lobbying by TherapeuticsMD, Inc.#

$220 K spent on lobbying the US Congress and federal agencies in 2022, most often on health issues.

Lobbying, 2022
$220 K
#824 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2022
2026 so far
—
  • Health Issues4 reports

Lobbying firms hired in 2022

Sims Strategies, LLC $220 K

TherapeuticsMD, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2022$220 K—4
2021$80 K—2
2018$0—7

How TherapeuticsMD, Inc. compares in Pharmaceutical

  • Market cap$23 M · higher than 9% of 393
  • Revenue$3 M · higher than 4% of 328
  • Net margin-6.4% · higher than 22% of 313
  • Revenue growth71.6% · higher than 92% of 107
  • Price / sales6.9× · lower than 18% of 219
  • Price / book0.8× · lower than 87% of 207

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
TherapeuticsMD, Inc.🇺🇸$23 M—-6.4%+71.6%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 14, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at TherapeuticsMD, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show TherapeuticsMD, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about TherapeuticsMD, Inc.? Suggest a correction